Non-Continuation of AHRQ Research and Training Awards: Sequence, Authority, and Portfolio Composition
This analysis examines 150 AHRQ research and training awards that did not receive continuation funding, comparing the agency's stated rationale with federal grant records, applicable regulations, and the subjects of the affected awards.
Between fall 2025 and summer 2026, AHRQ did not renew 150 research and training awards held by 78 institutions in 33 states — about $94 million that had been promised but not yet spent. The awards ended gradually, as each one's funding period expired without renewal. Most recipients learned why only when a form letter arrived on July 15, 2026, a median of nearly a year after their funding had already stopped.
AcademyHealth reviewed the federal grant record to understand what happened and how it compares with the reasons AHRQ gave. Here's what we found:
- The stated priorities don't fully explain the cuts. AHRQ said it was focusing its portfolio on priorities including patient safety, preventing antibiotic resistance, telehealth, and artificial intelligence. At least 52 of the 134 affected research awards were already working on one of those exact priorities — including a 40-hospital trial on reducing unnecessary antibiotic use, which was discontinued around the same time AHRQ funded a closely related study.
- Training awards make up a large share of the list. Many of the remaining awards were training and career-development grants, which prepare researchers rather than study a specific topic. Training the next generation of health services researchers is a function written into AHRQ's founding statute.
- We didn't find documentation of an award-by-award review. Federal rules call for continuation decisions to weigh each project's progress, management, and budget individually. The July 15 letters use identical language across very different projects, and the available federal record doesn't show that kind of individual review taking place.
- The awards still had time left on their approved schedules. Ending federal funding before a project's approved end date is generally treated as a distinct action with its own required steps, including notice and an opportunity to respond. That process doesn't appear to have been used here.
- The funding itself hasn't gone away. Congress allocated $214.1 million to this part of AHRQ's budget this year; less than 10% had been awarded with only weeks left in the fiscal year. A federal court has separately ordered AHRQ to preserve $70 million in related funds while litigation continues, and the Government Accountability Office has opened a review of the agency's spending practices.
This analysis doesn't take a position on which research priorities AHRQ should pursue because that's a legitimate call for the agency to make. What it asks is a narrower question: whether the process used to apply those priorities to existing awards followed the rules that govern federal research grants. Based on the available record, that's still an open question that matters for the researchers and institutions affected, and for how confidently the public can trust decisions made about publicly funded research.